Zoetis Inc. $ZTS Shares Sold by Triglav Investments D.O.O.

Triglav Investments D.O.O. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 69.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,977 shares of the company’s stock after selling 9,023 shares during the period. Triglav Investments D.O.O.’s holdings in Zoetis were worth $500,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the fourth quarter worth $25,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the fourth quarter worth about $32,000. Finally, Elyxium Wealth LLC bought a new position in shares of Zoetis during the fourth quarter worth about $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $77.81 on Friday. The firm has a 50-day moving average price of $104.29 and a 200 day moving average price of $117.03. The firm has a market capitalization of $32.62 billion, a PE ratio of 12.90, a P/E/G ratio of 1.28 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company posted $1.48 earnings per share. Zoetis’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on ZTS. Morgan Stanley restated an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday. Finally, Citigroup lowered their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $133.92.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.